ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision makingHans‐Joachim Schmoll, Andrés Cervantes, Eric Van Cutsem et al.|Annals of Oncology|2012Cited by 1.5k
Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 studyJosep Tabernero, Federico Nasroulah, Takayuki Yoshino et al.|The Lancet Oncology|2015Cited by 954
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trialFlorian Lordick, Markus Moehler, Yoon‐Koo Kang et al.|The Lancet Oncology|2013Cited by 838
Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancerJ.-Y. Douillard, R. Sidhu, Salvatore Siena et al.|Annals of Oncology|2014Cited by 603
Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trialAimery de Gramont, Paulo M. Hoff, Eric Van Cutsem et al.|The Lancet Oncology|2012Cited by 526